Business
Eastman manufactures specialty materials, additives, fibers and chemical intermediates.
Eastman's revenue and profit declined with chemical demand, but positive free cash flow and a grey-range balance sheet preserved flexibility through the downturn.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 6.7%Watch
- Profitability — Net income declined 47.6% to $474M from $905MWatch
- Cash flow — Free cash flow declined 38.4% to $424M from $688MWatch
- Margins — Comparable operating-margin data was unavailableNote
- Accounting — Cyclical decline with retained cash generationNote
- Insiders — 11 purchases and 1 salesOK
Where the revenue comes from
Fiscal 2025, as EASTMAN CHEMICAL CO reports it. History and quarterly detail are in the app.
- Advanced Materials$2.9B
- Additives And Functional Products$2.9B
- Chemical Intermediates$1.9B
- Fibers$1.1B
- Other Segments$17.0M
Leadership changes
From EASTMAN CHEMICAL CO's own filings, the day they're filed.
- Damon Audia · director · appointmenteff. 2025-06-27
- Donald W. Slager · director · appointmenteff. 2024-05-27
- Charles K. Stevens III · Directors · departureeff. 2024-02-13
Latest filings
- 10-Q · Quarterly report2026-07-31
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-05-12
- 10-Q · Quarterly report2026-05-01
- 8-K · Company announcement2026-04-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about EASTMAN CHEMICAL CO, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.